Der er risiko for præmatur fødsel (< 37 uger) såvel som hyperkaliæmi hos den nyfødte (forekomst hos 8 ud af 111 nyfødte. i. e.
In case of in utero exposure, monitoring of the newborn for the potential adverse events of tacrolimus is recommended (in particular effects on the kidneys). There is a risk for premature delivery (< 37 week) as well as for hyperkalaemia in the newborn (incidence 8 of 111 neonates, i. e.